SEC Comment Letter 0000000000-24-011352 to Q/C TECHNOLOGIES, INC. (QCLS)
Q/C TECHNOLOGIES, INC.
Date: Oct. 7, 2024 · CIK: 0001321834 · Accession: 0000000000-24-011352
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36268
Letter
October 7, 2024 Mitchell Glass President and Chief Medical Officer TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205 Re:TNF Pharmaceuticals, Inc. Form 10-K Filed April 1, 2024 File No. 001-36268 Dear Mitchell Glass: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Alla Digilova, Esq.
Show Raw Text
October 7, 2024
Mitchell Glass
President and Chief Medical Officer
TNF Pharmaceuticals, Inc.
855 N. Wolfe Street, Suite 623
Baltimore, MD 21205
Re:TNF Pharmaceuticals, Inc.
Form 10-K
Filed April 1, 2024
File No. 001-36268
Dear Mitchell Glass:
We have completed our review of your filing. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Alla Digilova, Esq.